Senti Biosciences (SNTI) Share-based Compensation (2021 - 2025)

Senti Biosciences has reported Share-based Compensation for 5 years, with the latest figure at $1.4 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation rose 135.54% year-over-year to $1.4 million; the trailing twelve-month figure through Dec 2025 stood at $5.7 million (up 225.13% YoY), and the FY2025 full-year result was $5.7 million, up 225.13% from the prior year.
• Share-based Compensation for Q4 2025 stood at $1.4 million, down from $1.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $9.2 million in Q2 2022, with the low at -$2.0 million in Q3 2023.
• Average Share-based Compensation over 5 years is $1.8 million, with a median of $1.3 million recorded in 2024.
• Year-over-year, Share-based Compensation soared 473.61% in 2022 and plunged 187.34% in 2023.
• Tracing SNTI's Share-based Compensation over 5 years: stood at $735000.0 in 2021, then soared by 473.61% to $4.2 million in 2022, then slumped by 51.04% to $2.1 million in 2023, then slumped by 70.69% to $605000.0 in 2024, then soared by 135.54% to $1.4 million in 2025.
• The last three Share-based Compensation figures came in at $1.4 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.

Peer Comparison